We tested the potential of our method to identify cancer drivers and thereby candidate drug targets in human cancer cells, using H358 lung cancer cells with the recurrent mono-allelic KRAS-G12C driver mutation as an example24. This evidence concerns the gene KRAS and lung cancer.